| BUSINESS SEGMENT INFORMATION |
11.
BUSINESS SEGMENT INFORMATION
As referenced above in Note 1, the Company operates in three reportable segments: Logistics, Life Sciences and Manufacturing.
The Company’s Chief Executive Officer, who is the Chief Operating Decision Maker (“CODM”), regularly reviews financial information at the reporting segment level in order to make decisions about resources to be allocated to the segments and to assess their performance.
The following tables present selected financial information about the Company’s reportable segments and Corporate for the purpose of reconciling to the consolidated totals for the three and six months ended March 31, 2026:
| | | | | | | | | | | | | | | | | | | | | | | For the three months ended March 31, 2026 | | Consolidated | | | Logistics | | | Life Sciences | | | Manufacturing | | | Corporate | | | Revenues | | $ | 57,444 | | | $ | 51,484 | | | $ | 3,401 | | | $ | 2,559 | | | $ | — | | | Forwarding expenses and cost of revenues | | | 38,876 | | | | 37,105 | | | | 622 | | | | 1,149 | | | | — | | | Gross profit | | | 18,568 | | | | 14,379 | | | | 2,779 | | | | 1,410 | | | | — | | | Selling, general and administrative | | | 16,194 | | | | 10,913 | | | | 2,306 | | | | 841 | | | | 2,134 | | | Amortization of intangible assets | | | 829 | | | | — | | | | — | | | | — | | | | 829 | | | Income (loss) from operations | | | 1,545 | | | | 3,466 | | | | 473 | | | | 569 | | | | (2,963 | ) | | Interest expense | | | 410 | | | | 272 | | | | 66 | | | | 66 | | | | 6 | | | Identifiable assets | | | 154,188 | | | | 68,433 | | | | 11,736 | | | | 7,398 | | | | 66,621 | | | Capital expenditures, net of disposals | | | 123 | | | | — | | | | 123 | | | | — | | | | — | |
| | | | | | | | | | | | | | | | | | | | | | | For the six months ended March 31, 2026 | | Consolidated | | | Logistics | | | Life Sciences | | | Manufacturing | | | Corporate | | | Revenues | | $ | 113,483 | | | $ | 102,313 | | | $ | 6,805 | | | $ | 4,365 | | | $ | — | | | Forwarding expenses and cost of revenues | | | 76,798 | | | | 73,534 | | | | 1,202 | | | | 2,062 | | | | — | | | Gross profit | | | 36,685 | | | | 28,779 | | | | 5,603 | | | | 2,303 | | | | — | | | Selling, general and administrative | | | 32,504 | | | | 21,891 | | | | 4,792 | | | | 1,773 | | | | 4,048 | | | Amortization of intangible assets | | | 1,658 | | | | — | | | | — | | | | — | | | | 1,658 | | | Income (loss) from operations | | | 2,523 | | | | 6,888 | | | | 811 | | | | 530 | | | | (5,706 | ) | | Interest expense | | | 715 | | | | 372 | | | | 192 | | | | 145 | | | | 6 | | | Identifiable assets | | | 154,188 | | | | 68,433 | | | | 11,736 | | | | 7,398 | | | | 66,621 | | | Capital expenditures, net of disposals | | | 164 | | | | 9 | | | | 151 | | | | 4 | | | | — | |
The Manufacturing segment includes results from Rubicon starting on the acquisition date of October 14, 2025. Rubicon’s corporate expenses are included in Janel’s Corporate expenses segment.
| |
|
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| The following tables present selected financial information about the Company’s reportable segments and Corporate for the purpose of reconciling to the consolidated totals for the three and six months ended March 31, 2025: |
| |
|
|
|
| |
|
| |
|
| |
|
| |
|
| For the three months ended March 31, 2025 |
|
Consolidated |
|
| Logistics |
|
| Life Sciences |
|
| Manufacturing |
|
| Corporate |
|
|
Revenues
|
|
$ |
50,731 | |
| $ |
44,044 | |
| $ |
4,166 | |
| $ |
2,521 | |
| $ |
— | |
|
Forwarding expenses and cost of revenues
|
|
|
34,160 | |
| |
32,188 | |
| |
796 | |
| |
1,176 | |
| |
— | |
|
Gross profit
|
|
|
16,571 | |
| |
11,856 | |
| |
3,370 | |
| |
1,345 | |
| |
— | |
|
Selling, general and administrative
|
|
|
13,759 | |
| |
9,524 | |
| |
1,918 | |
| |
802 | |
| |
1,515 | |
|
Amortization of intangible assets
|
|
|
642 | |
| |
— | |
| |
— | |
| |
— | |
| |
642 | |
|
Income (loss) from operations
|
|
|
2,170 | |
| |
2,332 | |
| |
1,452 | |
| |
543 | |
| |
(2,157 | ) |
|
Interest expense
|
|
|
560 | |
| |
395 | |
| |
90 | |
| |
75 | |
| |
— | |
|
Identifiable assets
|
|
|
114,314 | |
| |
44,603 | |
| |
12,629 | |
| |
4,794 | |
| |
52,288 | |
|
Capital expenditures, net of disposals
|
|
|
284 | |
| |
14 | |
| |
255 | |
| |
15 | |
| |
— | |
| |
|
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| For the six months ended March 31, 2025 |
|
Consolidated |
|
| Logistics |
|
| Life Sciences |
|
| Manufacturing |
|
| Corporate |
|
|
Revenues
|
|
$ |
102,085 | |
| $ |
90,130 | |
| $ |
7,149 | |
| $ |
4,806 | |
| $ |
— | |
|
Forwarding expenses and cost of revenues
|
|
|
70,372 | |
| |
66,896 | |
| |
1,246 | |
| |
2,230 | |
| |
— | |
|
Gross profit
|
|
|
31,713 | |
| |
23,234 | |
| |
5,903 | |
| |
2,576 | |
| |
— | |
|
Selling, general and administrative
|
|
|
27,051 | |
| |
18,892 | |
| |
3,917 | |
| |
1,743 | |
| |
2,499 | |
|
Amortization of intangible assets
|
|
|
1,283 | |
| |
— | |
| |
— | |
| |
— | |
| |
1,283 | |
|
Income (loss) from operations
|
|
|
3,379 | |
| |
4,342 | |
| |
1,986 | |
| |
833 | |
| |
(3,782 | ) |
|
Interest expense
|
|
|
1,226 | |
| |
879 | |
| |
207 | |
| |
140 | |
| |
— | |
|
Identifiable assets
|
|
|
114,314 | |
| |
44,603 | |
| |
12,629 | |
| |
4,794 | |
| |
52,288 | |
|
Capital expenditures, net of disposals
|
|
|
375 | |
| |
25 | |
| |
333 | |
| |
17 | |
| |
— | |
|